Renazorb News and Research

RSS

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.

8 Jan 2013

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced the initiation of patient enrollment in a Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb in healthy volunteers.

29 May 2012

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals, Inc. a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

6 Aug 2009